WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc.

May 26, 2005 09:00 ET

WEX Pharmaceuticals Inc.: New Director of Intellectual Property

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 26, 2005) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) is pleased to announce that Dr. Euan Taylor has accepted the position of Director of Intellectual Property with the Company. Dr. Taylor has a B.A in Natural Sciences from the University of Cambridge, a Ph.D. in developmental molecular biology from the University of London and a law degree from the University of British Columbia. He is also a registered Canadian Patent Agent and a Registered Canadian Trademark Agent.

Dr. Taylor brings to WEX extensive experience in the field of intellectual property. He articled and worked at Ladner Downs (now Borden Ladner Gervais LLP) and later moved to the intellectual property group at Davis & Company, where he focused on the prosecution of patent and trademark applications and the enforcement and transfer of rights in intellectual property. Dr. Taylor was recently with Smart & Biggar where he focused almost exclusively on the drafting and prosecution of patent applications in the Life Sciences field. During his postdoctoral research Dr. Taylor also worked in cancer research and on plant gene expression.

"We are excited to have attracted someone of the caliber of Dr. Euan Taylor," said Frank Shum, President and CEO. "His appointment is inline with the Company's intentions of implementing a strong senior management team and his expertise will help strengthen our I.P. protection around our portfolio of products as we move forward to achieving commercialization."

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is a company dedicated to the discovery of new therapeutic agents for the treatment of moderate to severe pain, symptom relief associated with addiction withdrawal from opioid abuse, and medicines designed for local and regional anaesthesia. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the Global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China and are expanding its marketing efforts in the rest of Asia.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Contact Information

  • WEX Pharmaceuticals Inc.
    Don Evans
    Corporate Communications
    (604) 683-8880 or 1-800-722-7549
    WEX Pharmaceuticals Inc.
    Gordon Stanley
    Corporate Communications
    (604) 683-8880 or 1-800-722-7549
    (604) 683-8868 (FAX)